VIKING THERAPEUTICS INC (VKTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$24.40-5.54%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge VIKING THERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.086
Annual ending 2026-12-31
Revenue	—	7.17M
EPS	—	-4.598
Annual ending 2027-12-31
Revenue	—	7.35M
EPS	—	-4.346

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
sufficient cash to fund operations and pipeline development	A supporting condition in VIKING THERAPEUTICS INC's published investment case. The stated target is cash runway extends beyond 12 months without dilutive financing.	Intact	cash runway falls below 12 months without clear financing plan	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
improvement in EPS losses	A primary condition in VIKING THERAPEUTICS INC's published investment case. The stated target is EPS loss improves from -$1.37 next quarter to less negative by end 2026.	Improving	EPS loss worsens beyond -$1.5 next quarter or fails to improve by end 2026	Diluted EPS: $-1.10 per share FY2026-Q2; GAAP. Published target: EPS loss improves from -$1.37 next quarter to less negative by end 2026. Target period is not explicitly aligned with this observation. Source published Jul 29, 2026-1.1 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0f944cc0-a958-4caa-85df-ed596f995cde. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
advancement of VK2735 obesity program and other pipeline assets	Despite losses, recent progress in obesity drug VK2735 could lead to future value.	Improving	failure to meet key clinical or regulatory milestones for VK2735 by end 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.35

$-4.57 → $-4.35 · observed estimates

FY2027 revenue$0.01B

$0.00B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.57	$0	17 / 17
2026-07-25	$-4.57	$0	17 / 17
2026-07-26	$-4.57	$0	17 / 17
2026-07-27	$-4.57	$0	17 / 17
2026-07-28	$-4.57	$0	17 / 17
2026-07-29	$-4.77	$7,349,020	15 / 10
2026-07-30	$-4.54	$0	17 / 16
2026-07-31	$-4.39	$0	17 / 18
2026-08-01	$-4.42	$7,349,020	15 / 11
2026-08-02	$-4.42	$7,349,020	15 / 11
2026-08-03	$-4.42	$7,349,020	15 / 11
2026-08-04	$-4.39	$0	17 / 18
2026-08-05	$-4.42	$7,349,020	15 / 11
2026-08-06	$-4.33	$0	17 / 18
2026-08-08	$-4.42	$7,349,020	15 / 11
2026-08-09	$-4.33	$0	17 / 18
2026-08-10	$-4.33	$0	17 / 18
2026-08-12	$-4.42	$7,349,020	15 / 11
2026-08-13	$-4.42	$7,349,020	15 / 11
2026-08-14	$-4.42	$7,349,020	15 / 11
2026-08-15	$-4.42	$7,349,020	15 / 11
2026-08-16	$-4.42	$7,349,020	15 / 11
2026-08-17	$-4.42	$7,349,020	15 / 11
2026-08-18	$-4.42	$7,349,020	15 / 11
2026-08-19	$-4.42	$7,349,020	15 / 11
2026-08-20	$-4.39	$7,349,020	15 / 11
2026-08-21	$-4.39	$7,349,020	15 / 11
2026-08-22	$-4.39	$7,349,020	15 / 11
2026-08-23	$-4.39	$7,349,020	15 / 11
2026-08-24	$-4.39	$7,349,020	15 / 11
2026-08-25	$-4.39	$7,349,020	15 / 11
2026-08-26	$-4.39	$7,349,020	15 / 11
2026-08-27	$-4.39	$7,349,020	15 / 11
2026-08-28	$-4.39	$7,349,020	15 / 11
2026-08-29	$-4.39	$7,349,020	15 / 11
2026-08-30	$-4.39	$7,349,020	15 / 11
2026-08-31	$-4.39	$7,349,020	15 / 11
2026-09-01	$-4.39	$7,349,020	15 / 11
2026-09-02	$-4.39	$7,349,020	15 / 11
2026-09-03	$-4.39	$7,349,020	15 / 11
2026-09-04	$-4.39	$7,349,020	15 / 11
2026-09-05	$-4.39	$7,349,020	15 / 11
2026-09-06	$-4.39	$7,349,020	15 / 11
2026-09-07	$-4.39	$7,349,020	15 / 11
2026-09-08	$-4.39	$7,349,020	15 / 11
2026-09-09	$-4.39	$7,349,020	15 / 11
2026-09-10	$-4.39	$7,349,020	15 / 11
2026-09-11	$-4.39	$7,349,020	15 / 11
2026-09-12	$-4.39	$7,349,020	15 / 11
2026-09-13	$-4.39	$7,349,020	15 / 11
2026-09-14	$-4.39	$7,349,020	15 / 11
2026-09-15	$-4.39	$7,349,020	15 / 11
2026-09-16	$-4.39	$7,349,020	15 / 11
2026-09-17	$-4.39	$7,349,020	15 / 11
2026-09-18	$-4.39	$7,349,020	15 / 11
2026-09-19	$-4.39	$7,349,020	15 / 11
2026-09-20	$-4.39	$7,349,020	15 / 11
2026-09-21	$-4.39	$7,349,020	15 / 11
2026-09-22	$-4.39	$7,349,020	15 / 11
2026-09-23	$-4.39	$7,349,020	15 / 11
2026-09-24	$-4.39	$7,349,020	15 / 11
2026-09-25	$-4.39	$7,349,020	14 / 10
2026-09-26	$-4.39	$7,349,020	14 / 10
2026-09-27	$-4.39	$7,349,020	14 / 10
2026-09-28	$-4.39	$7,349,020	14 / 10
2026-09-29	$-4.39	$7,349,020	14 / 10
2026-09-30	$-4.39	$7,349,020	14 / 10
2026-10-01	$-4.39	$7,349,020	14 / 10
2026-10-02	$-4.39	$7,349,020	14 / 10
2026-10-03	$-4.39	$7,349,020	14 / 10
2026-10-04	$-4.39	$7,349,020	14 / 10
2026-10-05	$-4.39	$7,349,020	14 / 10
2026-10-06	$-4.39	$7,349,020	14 / 10
2026-10-07	$-4.39	$7,349,020	14 / 10
2026-10-08	$-4.39	$7,349,020	14 / 10
2026-10-09	$-4.39	$7,349,020	14 / 10
2026-10-10	$-4.39	$7,349,020	14 / 10
2026-10-11	$-4.39	$7,349,020	14 / 10
2026-10-12	$-4.39	$7,349,020	14 / 10
2026-10-13	$-4.39	$7,349,020	14 / 10
2026-10-14	$-4.39	$7,349,020	14 / 10
2026-10-15	$-4.36	$7,349,020	14 / 10
2026-10-16	$-4.36	$7,349,020	15 / 10
2026-10-17	$-4.36	$7,349,020	15 / 10
2026-10-18	$-4.36	$7,349,020	15 / 10
2026-10-19	$-4.36	$7,349,020	15 / 10
2026-10-20	$-4.36	$7,349,020	15 / 10
2026-10-21	$-4.35	$7,349,020	15 / 10
2026-10-22	$-4.35	$7,349,020	15 / 10
2026-10-23	$-4.35	$7,349,020	15 / 10
2026-10-24	$-4.35	$7,349,020	15 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	18	2
2026-06-01	18	2
2026-07-01	18	2
2026-08-01	18	2
2026-09-01	18	2
2026-10-01	19	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 19 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Truist FinancialOct 7 · prior Sep 23

$87.00 → $85.00-2.3%

$0$47.85$95.70

0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

sufficient cash to fund operations and pipeline developmentDirect metric needs a verified mapping
improvement in EPS lossesDiluted EPS: $-1.10 per share
advancement of VK2735 obesity program and other pipeline assetsDirect metric needs a verified mapping

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-42.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

VIKING THERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage growth story, not an established earnings compounder. The long-term thesis is intact but in a watch state, with management advancing several clinical programs while recent financial performance remains weak.

What's priced into VIKING THERAPEUTICS INC

The evidence gives no valuation measure or clear account of market expectations, so whether VKTX is cheap or expensive versus peers cannot be judged here. The priced-in fragility assessment is low, but that does not establish that expectations are modest.

What the fundamentals likely do

Over the multi-year view, progress depends on advancing VK2735 through Phase 3 and starting its oral Phase 3 trial, while VK3019 moves through early testing. Management has reported the main VK2735 Phase 3 trials on track, positive maintenance-study results, and a planned Phase 1 start for VK3019. Near term, the company remains loss-making, recent performance is weak, and the next report carries elevated miss risk.

What VIKING THERAPEUTICS INC hinges on

The thesis strengthens if clinical programs keep meeting milestones and the next call does not bring a guidance cut. A guidance cut, weakening employment data and recession concerns could weigh on the near-term setup; continued strength among major healthcare peers could support sector sentiment.